Loading...
Alnylam Pharmaceuticals, Inc.
0HD2.L•LSE
Healthcare
Medical - Pharmaceuticals
£322.40
£0.04(0.01%)
Alnylam Pharmaceuticals, Inc. (0HD2.L) AI-Powered Stock Analysis
See how Alnylam Pharmaceuticals, Inc. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerAlnylam Pharmaceuticals, Inc. (0HD2.L) Stock Overall Grade
Alnylam Pharmaceuticals, Inc.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
B+
Good
Grade Breakdown by Metric
See how each financial and market factor contributes to Alnylam Pharmaceuticals, Inc.'s overall stock rating.
Forecast
A+Score
100/100Financial Growth
A+Score
100/100Fundamental Growth
C+Score
51/100Key Ratios
C+Score
57/100Sector Comparison
B+Score
75/100Industry Comparison
AScore
80/100S&P 500 Benchmark
AScore
85/100Analyst Consensus
C+Score
50/100Alnylam Pharmaceuticals, Inc. (0HD2.L) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 100/100 (A+), reflecting high confidence in its potential. Financial Growth (100/100, A+) and Fundamental Growth (51/100, C+) highlight its stability, while Key Ratios (57/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (85/100, A), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Alnylam Pharmaceuticals, Inc. stock grade, including financials, comparisons, and forecasts.